Absence of Pittsburgh compound B detection of cerebral amyloid β in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: A case report

Archives of Neurology

Volumn 66, Issue 12, 2009, Pages 1557-1562

  Cairns, Nigel J ^a,b   Ikonomovic, Milos D ^c   Benzinger, Tammie ^a,b   Storandt, Martha ^a,b   Fagan, Anne M ^a,b   Shah, Aarti R ^a,b   Reinwald, Lisa Taylor ^a   Carter, Deborah ^a   Felton, Angela ^a   Holtzman, David M ^a,b   Mintun, Mark A ^a,b   Klunk, William E ^c   Morris, John C ^a,b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; CORTICOSTERONE; PITTSBURGH COMPOUND B; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; VASCULAR AMYLOIDOSIS;

AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANILINE COMPOUNDS; BIOLOGICAL MARKERS; CARBON RADIOISOTOPES; CEREBRAL CORTEX; COGNITION DISORDERS; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; THIAZOLES;

EID: 73549123897     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.279     Document Type: Article

References (39)

1. Frank RA, Galasko D, Hampel H, et al; National Institute on Aging Biological Markers Working Group. Biological markers for therapeutic trials in Alzheimer's disease: proceedings of the Biological Markers Working Group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging. 2003;24(4): 521-536.
2. Morris JC, Holtzman DM, Quaid KA, et al. The role of biomarkers in studies of presymptomatic Alzheimer's disease. Alzheimers Dement. 2005;1(2):145-151.
3. Mathis CA, Lopresti BJ, Klunk WE. Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol. 2007;34(7):809-822.
4. Sonnen JA, Montine KS, Quinn JF, Kaye JA, Breitner JCS, Montine TJ. Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol. 2008; 7(8):704-714.
5. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319.
6. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann Neurol. 2006;59 (3):512-519.
7. 42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343-349.
8. Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid AB42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65(2):176-183.
9. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol. 2009;65(4):403-413.
10. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452.
11. Pike KE, Savage G, Villemagne VL, et al. β-Amyloid imaging and memory in nondemented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007; 130(pt 11):2837-2844.
12. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509-1517.
13. Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66(12):1469-1475.
14. Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathological outcomes in original versus revised MCI and in pre-MCI. Neurology. 2006;67(3):467-473.
15. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
16. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.
17. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer disease centers. Alzheimer Dis Assoc Disord. 2006;20(4):210-216.
18. Wechsler D, Stone CP. Manual: Wechsler Memory Scale. New York, NY: Psychological Corp; 1973.
19. Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology. 1988;38(6):900-903.
20. Wechsler D. Manual: Wechsler Adult Intelligence Scale. New York, NY: Psychological Corp; 1955.
21. Goodglass H, Kaplan E. Boston Naming Test Scoring Booklet. Philadelphia, PA: Lea & Febiger; 1983.
22. Thurstone LL, Thurstone LG. Examiner Manual for the SRA Primary Mental Abilities Test. Chicago, IL: Science Research Associates; 1949.
23. Armitage SG. An analysis of certain psychological tests used in the evaluation of brain injury. Psych Mono. 1946;60:1-48.
24. Johnson DK, Storandt M, Morris J, Galvin JE. Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol. 2009;66(10):1254-1259. doi:10.1001/archneurol2009.158.
25. Pastor P, Roe CM, Villegas A, et al. Apolipoprotein Eε4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol. 2003;54(2):163-169.
26. Behrens MI, Mukherjee O, Tu PH, et al. Neuropathologic heterogeneity in HDDD1: a familial frontotemporal lobar degeneration with ubiquitin-positive inclusions and progranulin mutation. Alzheimer Dis Assoc Disord. 2007;21(1):1-7.
27. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131(pt 6):1630-1645.
28. Ikonomovic MD, Abrahamson EE, Isanski BA, et al. X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease. Methods Enzymol. 2006;412:123-144.
29. Fagan AM, Younkin LH, Morris JC, et al. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann Neurol. 2000;48:201-210.
30. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.
31. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease - associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389-404.
32. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol. 1985;42(11):1097-1105.
33. Mirra SS, Heyman A, McKeel DW, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41(4):479-486.
34. National Institute on Aging, Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging. 1997;18(4)(suppl):S1-S2.
35. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56(3):303-308.
36. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer's disease. Arch Neurol. 2001;58(3):397-405.
37. Shankar GM, Li S, Mehta TH, et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008; 14(8):837-842.
38. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64(3):431-434.
39. Storandt M. Cognitive deficits in the early stages of Alzheimer's disease. Curr Dir Psychol Sci. 2008;17:198-202.